PMID- 23807528
OWN - NLM
STAT- MEDLINE
DCOM- 20140721
LR  - 20221207
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 19
IP  - 6
DP  - 2013 Nov-Dec
TI  - Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 
      diabetes insufficiently controlled with metformin and a sulfonylurea.
PG  - 980-8
LID - 10.4158/EP13148.OR [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of add-on pioglitazone versus 
      sitagliptin in patients with type 2 diabetes inadequately controlled on metformin 
      and a sulfonylurea (SU). METHODS: This 24-week, randomized, open-label study 
      compared pioglitazone (30 mg daily, n = 59) and sitagliptin (100 mg daily, n = 
      60) in patients with inadequate glycemic control (glycosylated hemoglobin [HbA1c] 
      >/=7.0% to <11.0%) while receiving a stable dose of metformin (>/=1,500 mg daily) and 
      an SU (>/=half-maximal dose). RESULTS: The mean changes in HbA1c from baseline was 
      -0.94 +/- 0.12% with pioglitazone and -0.71 +/- 0.12% with sitagliptin, for a 
      between-groups difference of -0.23 +/- 0.16% (P = .16). The mean change in fasting 
      plasma glucose (FPG) were -35.7 +/- 4.0 mg/dL with pioglitazone and -22.8 +/- 4.0 
      mg/dL with sitagliptin, for a between-groups difference of -12.9 +/- 5.7 mg/dL (P = 
      .02). Pioglitazone was associated with a significant decrease in high-sensitive 
      C-reactive protein (hs-CRP), but sitagliptin did not. The mean weight gain was 
      higher in the pioglitazone group, with a between-group difference of 1.6 kg 
      (P<.01). Overall adverse events (AEs) were similar in both groups. However, the 
      incidence of edema was higher with pioglitazone, and the incidence of 
      gastrointestinal AEs was higher with sitagliptin. CONCLUSION: Pioglitazone and 
      sitagliptin achieved similar improvements in overall glycemic control in patients 
      with type 2 diabetes inadequately controlled with metformin and an SU. However 
      there were some differences in terms of FPG, hs-CRP, lipids, body-weight change, 
      and AEs.
FAU - Liu, Sung-Chen
AU  - Liu SC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay 
      Memorial Hospital Epidemiology & Institute of Preventive Medicine, College of 
      Public Health, National Taiwan University, Taipei, Taiwan.
FAU - Chien, Kuo-Liong
AU  - Chien KL
FAU - Wang, Chao-Hung
AU  - Wang CH
FAU - Chen, Wei-Che
AU  - Chen WC
FAU - Leung, Ching-Hsiang
AU  - Leung CH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Pyrazines)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Triazoles)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9100L32L2N (Metformin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - Blood Glucose/analysis
MH  - C-Reactive Protein/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin/blood
MH  - Male
MH  - Metformin/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Pioglitazone
MH  - Prospective Studies
MH  - Pyrazines/adverse effects/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Sulfonylurea Compounds/adverse effects/*therapeutic use
MH  - Thiazolidinediones/adverse effects/*therapeutic use
MH  - Triazoles/adverse effects/*therapeutic use
MH  - Weight Gain/drug effects
EDAT- 2013/06/29 06:00
MHDA- 2014/07/22 06:00
CRDT- 2013/06/29 06:00
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2014/07/22 06:00 [medline]
AID - S1530-891X(20)43132-5 [pii]
AID - 10.4158/EP13148.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2013 Nov-Dec;19(6):980-8. doi: 10.4158/EP13148.OR.